17 March 2016 - Bio Products Laboratory today announced that the EMA has granted marketing authorisation for Coagadex. Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is the first and only treatment licensed specifically for this rare bleeding disorder in Europe.

For more details, go to: http://www.bpl.co.uk/about-bpl/news/q/date/2016/03/17/press-release-bio-products-laboratory-receives-european-approval-for-coagadex-human-coagulation-factor-x-first-ever-treatment-for-rare-bleeding-disorder-hereditary-factor-x-deficiency/